Mental Health
Stress physiology, focus, anxiety, mood — protocols, practices, and pharmacology.
From the magazine · 9
All articles →Psychedelic Treatment Luvesilocin Shows Promise for Postpartum Depression and Anxiety
A new psychedelic compound, luvesilocin, is undergoing FDA clinical trials for postpartum depression and anxiety, showing promising results in early studies. This treatment could offer a novel approach to conditions affecting nearly 20% of new mothers.
Self-Compassion and Psychological Flexibility Linked to Remission in Process-Based Therapy for Anxiety and Depression
A retrospective study suggests that improvements in self-compassion and psychological flexibility are key factors in achieving remission from anxiety and depression symptoms among individuals undergoing Process-Based Therapy (PBT) [1]. These findings highlight potential targets for enhancing mental health interventions.
Psychedelics and OCD: A Circuit-Based Framework for Therapeutic Approaches
A new review explores how classic psychedelics like LSD and psilocybin might offer a therapeutic pathway for Obsessive-Compulsive Disorder (OCD) by targeting maladaptive brain circuits and enhancing neuroplasticity. The authors propose that these substances could help reset pathological patterns and improve brain network connectivity in individuals with OCD.
Creatine Shows Early Promise as Adjunctive Depression Treatment, but Evidence Is Mixed
A new review suggests that creatine, a popular muscle-building supplement, may offer additional benefits for some individuals with depression by supporting brain energy. However, the evidence is inconsistent, with some studies showing positive effects and others finding no significant improvement.
Adolescent Cannabis Use Linked to Increased Risk of Psychotic and Bipolar Disorders
A large-scale study involving over 463,000 adolescents suggests a significant association between cannabis use in teenage years and a heightened risk of developing serious mental health conditions, including psychotic and bipolar disorders, later in young adulthood. The research indicates that cannabis use often preceded these diagnoses by nearly two years.
Mental Health Crisis Among Early-Career Researchers: A Comprehensive Review
A new systematic review and meta-analysis reveals that nearly 30% of early-career researchers experience elevated psychological distress, with rates of depression and anxiety significantly higher than in the general population.
Psychedelic therapy: state of the clinical evidence
Psychedelic-assisted therapy is no longer a fringe idea, but the evidence is uneven. The strongest signals are for depression and PTSD, while durability, safety, and the role of psychotherapy still need sharper trials.
Meditation and brain structure: what neuroimaging really shows
Neuroimaging suggests meditation is linked to subtle differences in brain structure and function, but the strongest claims still outrun the data. Most findings are small, heterogeneous, and not yet proof of lasting rewiring.
Exercise as an antidepressant: what dose seems to work best?
Exercise can reduce depressive symptoms, and newer evidence suggests the antidepressant effect is dose-sensitive rather than all-or-nothing. The strongest signals come from moderate, repeated aerobic training, with bigger effects in more structured programs.